Cell Signaling Technology

Product Pathways - Neuroscience

FE65 Antibody #2877

Applications Reactivity Sensitivity MW (kDa) Source
W M R (H) Endogenous 100 Rabbit

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human  M=Mouse  R=Rat
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

FE65 Antibody detects endogenous levels of FE65. It does not cross-react with FE65L1 or FE65L2.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues of human FE65. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from wild type (WT), FE65 knock-out (65KO), FE65L1 knock-out (L1KO) and FE65/FE65L1 double knock-out (DKO) mouse brain lysates, using FE65 Antibody. (Kindly provided by Dr. Suzanne Guénette, MassGeneral Institute for Neurodegenerative Disease, Charlestown, Massachusetts).

Western Blotting

Western Blotting

Western blot analysis of extracts from mouse and rat brain, using FE65 Antibody.

Background

FE65, FE65L1 and FE65L2 are members of the FE65 protein family. FE65 is an adaptor protein with protein-protein interaction domains including a WW domain followed by two phosphotyrosine interaction domains (PID1 and PID2) (1). Amyloid beta precursor protein (APP) binds to PID2 and undergoes sequential cleavage. First alpha-/beta secretases cleave and release the ectodomain into the extracellular environment. Subsequent processing by the gamma-secretase complex results in the APP intracellular domain (AICD) and the beta-amyloid peptides. The latter A-beta fragments form the main components of amyloid plaques in patients with Alzheimer's disease (2). FE65 family members can regulate APP processing, resulting in elevated levels of A-beta (3). Double knock-out mice of FE65 and FE65L1 display a phenotype that occurs in animals lacking APP family members, supporting a functional interaction between FE65 and APP (4).

  1. Russo, T. et al. (1998) FEBS Lett 434, 1-7.
  2. Selkoe, D.J. (1996) J Biol Chem 271, 18295-8.
  3. King, G.D. and Scott Turner, R. (2004) Exp Neurol 185, 208-19.
  4. Guénette, S. et al. (2006) EMBO J 25, 420-31.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products